Shankar Vallabhajosula

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi request reprint (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization
    Shankar Vallabhajosula
    Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital, Cornell University, New York, NY 10021, USA
    Semin Nucl Med 37:400-19. 2007
  2. ncbi request reprint Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity
    Shankar Vallabhajosula
    Department of Radiology, Division of Nuclear Medicine, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York 10021, USA
    Clin Cancer Res 11:7195s-7200s. 2005
  3. doi request reprint A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new?
    Shankar Vallabhajosula
    Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Weill Cornell Medical College of Cornell University and New York Presbyterian Hospital, USA
    Semin Nucl Med 41:246-64. 2011
  4. doi request reprint Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors
    Shankar Vallabhajosula
    Department of Radiology, Weill Cornell Medical College of Cornell University, Nuclear Medicine, STARR 221, New York, NY 10065, USA
    Semin Nucl Med 40:220-41. 2010
  5. ncbi request reprint Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen
    Shankar Vallabhajosula
    Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital Weill Medical College of Cornell University, 525 E 68th Street, STARR 221, New York, NY 10021, USA
    J Nucl Med 46:850-8. 2005
  6. doi request reprint Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology
    Shankar Vallabhajosula
    Department of Radiology, Weill Cornell Medical College of Cornell University, New York, NY, USA
    Semin Nucl Med 41:324-33. 2011
  7. ncbi request reprint Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
    Shankar Vallabhajosula
    Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, New York, USA
    J Nucl Med 46:634-41. 2005
  8. doi request reprint Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid
    Shankar Vallabhajosula
    Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Weill Cornell Medical College of Cornell University and New York Presbyterian Hospital, NY, USA
    Semin Nucl Med 41:283-99. 2011
  9. ncbi request reprint Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice
    Shankar Vallabhajosula
    Department of Radiology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York 10021, USA
    Prostate 58:145-55. 2004
  10. ncbi request reprint Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor
    Peter M Smith-Jones
    Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, NY 10021, USA
    J Nucl Med 44:610-7. 2003

Detail Information

Publications34

  1. ncbi request reprint (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization
    Shankar Vallabhajosula
    Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital, Cornell University, New York, NY 10021, USA
    Semin Nucl Med 37:400-19. 2007
    ..The potential routine clinical utility of (18)F-labeled PET radiopharmaceuticals depends also on regulatory compliance in addition to documentation of potential safety and efficacy by various investigators...
  2. ncbi request reprint Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity
    Shankar Vallabhajosula
    Department of Radiology, Division of Nuclear Medicine, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York 10021, USA
    Clin Cancer Res 11:7195s-7200s. 2005
    ..Fractionated dose regimens may decrease myelotoxicity and increase greater total administered dose. We have studied the effect of two or three treatments of 177Lu-J591 and 90Y-J591 monoclonal antibodies (mAb) on myelotoxicity...
  3. doi request reprint A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new?
    Shankar Vallabhajosula
    Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Weill Cornell Medical College of Cornell University and New York Presbyterian Hospital, USA
    Semin Nucl Med 41:246-64. 2011
    ..This review briefly describes the chemistry, mechanisms(s) of localization, and clinical application of both proprietary and nonproprietary new PET drugs under multicenter clinical evaluation...
  4. doi request reprint Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors
    Shankar Vallabhajosula
    Department of Radiology, Weill Cornell Medical College of Cornell University, Nuclear Medicine, STARR 221, New York, NY 10065, USA
    Semin Nucl Med 40:220-41. 2010
    ..This review provides a comprehensive summary of various factors and specific examples to illustrate the significance of altered biodistribution of radiopharmaceuticals...
  5. ncbi request reprint Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen
    Shankar Vallabhajosula
    Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital Weill Medical College of Cornell University, 525 E 68th Street, STARR 221, New York, NY 10021, USA
    J Nucl Med 46:850-8. 2005
    ....
  6. doi request reprint Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology
    Shankar Vallabhajosula
    Department of Radiology, Weill Cornell Medical College of Cornell University, New York, NY, USA
    Semin Nucl Med 41:324-33. 2011
    ..The very high SA of n.c.a. [(131)I]MIBG drug would increase the specific cellular uptake of adrenergic neurons and neuroendocrine tumor cells expressing NET...
  7. ncbi request reprint Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
    Shankar Vallabhajosula
    Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, New York, USA
    J Nucl Med 46:634-41. 2005
    ..The radiation dosimetry of 90Y-J591 was estimated based on both 111In and 177Lu data to validate the usage of 111In as a chemical and biologic surrogate for 90Y...
  8. doi request reprint Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid
    Shankar Vallabhajosula
    Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Weill Cornell Medical College of Cornell University and New York Presbyterian Hospital, NY, USA
    Semin Nucl Med 41:283-99. 2011
    ..In addition, PET amyloid imaging will also help test the amyloid cascade hypothesis of AD and as an aid to assess the efficacy of antiamyloid therapeutics currently under development in clinical trials...
  9. ncbi request reprint Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice
    Shankar Vallabhajosula
    Department of Radiology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York 10021, USA
    Prostate 58:145-55. 2004
    ..Radiolabeled J591 monoclonal antibody (MAb) binds with high affinity to an extracellular epitope of PSMA and localizes specifically in PSMA positive LNCaP tumors in vivo...
  10. ncbi request reprint Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor
    Peter M Smith-Jones
    Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, NY 10021, USA
    J Nucl Med 44:610-7. 2003
    ..This article reports on the in vivo behavior and tumor uptake of (131)I- and (111)In-labeled antiPSMA(ext) mAbs (J415, J533, and J591) and their potential utility for radioimmunotherapy...
  11. ncbi request reprint Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement
    Jodi V Mones
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Lymphoma 48:342-8. 2007
    ..Two patients had objective responses of 1 and 42.4+ months, respectively. RIT with attenuated dose iodine 131 tositumomab for patients with >25% BMI has acceptable toxicity and can result in lymphoma responses...
  12. ncbi request reprint Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen
    Neil H Bander
    Department of Urology, Division of Nuclear Medicine, New York Presbyterian Hospital Weill Medical College of Cornell University, 525 East 68th Street, Starr 900, New York, NY 10021, USA
    J Urol 170:1717-21. 2003
    ....
  13. pmc Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents
    Lisa Mosconi
    Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    Neurobiol Aging 34:22-34. 2013
    ..NH and ≥ 71% for MH vs. PH, with relative risk = 1.9-5.1 (p values < 0.005). NL individuals with AD-affected mothers show co-occurring Aβ increases and hypometabolism in AD-vulnerable regions, suggesting an increased risk for AD...
  14. ncbi request reprint Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma
    Alan D Dosik
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
    Cancer 106:616-22. 2006
    ..Hematologic reserve after radioimmunotherapy (RIT) is an important consideration when subsequent therapy is required...
  15. pmc Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer
    Scott T Tagawa
    Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, USA
    Cancer 116:1075-83. 2010
    ..Future studies will include approaches to optimize patient selection and incorporate novel strategies to improve the success of anti-PSMA radioimmunotherapy...
  16. ncbi request reprint Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors
    Matthew I Milowsky
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York 10021, USA
    J Clin Oncol 25:540-7. 2007
    ..This was a proof-of-principle evaluation of PSMA as a potential neovascular target. The primary end points were targeting,toxicity, maximum-tolerated dose, pharmacokinetics (PK), and human antihuman antibody (HAHA) response...
  17. pmc PET imaging of leptin biodistribution and metabolism in rodents and primates
    Giovanni Ceccarini
    Laboratory of Molecular Genetics, Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA
    Cell Metab 10:148-59. 2009
    ....
  18. ncbi request reprint Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
    Neil H Bander
    Department of Urology, Weill Medical College of Cornell University, 525 E 68th St, E 300, New York, NY 10021, USA
    J Clin Oncol 23:4591-601. 2005
    ....
  19. ncbi request reprint The utility of monoclonal antibodies in the imaging of prostate cancer
    Daniel Yao
    James Buchanan Brady Department of Urology, The New York Presbyterian Hospital Weill Medical College of Cornell University, New York, NY 10021, USA
    Semin Urol Oncol 20:211-8. 2002
    ..Radioimmunoscintigraphy with this immunoconjugate has demonstrated excellent tumor targeting of prostate cancer sites not only in soft tissue but also in bone...
  20. ncbi request reprint Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method?
    Shota Konishi
    Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY 10021, USA
    Cancer Biother Radiopharm 19:706-15. 2004
    ..The alternate method, based on a fixed antigen concentration, appears to be practical and may provide a more reliable measure of immunoreactivity...
  21. ncbi request reprint Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer
    Matthew I Milowsky
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    J Clin Oncol 22:2522-31. 2004
    ....
  22. ncbi request reprint Clinical utility of radiolabeled monoclonal antibodies in prostate cancer
    Kevin A David
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Genitourin Cancer 4:249-56. 2006
    ..Additional studies are under way to better define the activity of radiolabeled antibody therapy as well as the role for fractionated therapy and combination approaches with taxane-based chemotherapy...
  23. pmc Maternal age affects brain metabolism in adult children of mothers affected by Alzheimer's disease
    Lisa Mosconi
    New York University School of Medicine, New York, NY 10016, USA
    Neurobiol Aging 33:624.e1-9. 2012
    ..There were no associations between paternal age and metabolism in any group. Evidence for a maternally inherited, maternal age-related mechanism provides further insight on risk factors and genetic transmission in late-onset AD...
  24. doi request reprint Clinically proven radiopharmaceuticals for infection imaging: mechanisms and applications
    Stanley J Goldsmith
    Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY 10021, USA
    Semin Nucl Med 39:2-10. 2009
    ..In this work, we review the features of each of these agents and discuss the issues involved in their use as radiopharmaceuticals for the identification of inflammation and/or infection...
  25. pmc Prostate-specific membrane antigen-based imaging
    Joseph R Osborne
    Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA
    Urol Oncol 31:144-54. 2013
    ..While advances in conventional imaging will continue, Ab and small molecule imaging exemplified by PSMA targeting have the greatest potential to improve diagnostic sensitivity and specificity...
  26. doi request reprint Site-specific (18)F-labeling of the protein hormone leptin using a general two-step ligation procedure
    Robert R Flavell
    Laboratory of Synthetic Protein Chemistry, Laboratory of Molecular Genetics, Howard Hughes Medical Institute, The Rockefeller University, New York, New York 10065, USA
    J Am Chem Soc 130:9106-12. 2008
    ..These protocols will allow for the routine production of site-specifically (18)F radiolabeled leptin, as well as other proteins, for use in PET imaging in systems from mouse to man...
  27. ncbi request reprint Investigation of the role of the base in the synthesis of [18F]FLT
    Makiko Suehiro
    Citigroup Biomedical Imaging Center, Weill Medical College of Cornell University, 516 East 72nd Street, New York, NY 10021, USA
    Appl Radiat Isot 65:1350-8. 2007
    ..When the precursor-to-base ratio was optimal, an overall [18F]FLT yield of 30-40% was achieved even if the precursor amount was as small as 8-13 mg...
  28. ncbi request reprint Early assessment of radiation response using a novel functional imaging modality -- [18F]fluorocholine PET (FCH-PET): a pilot study
    Bhupesh Parashar
    Stich Radiation Center, Weill Cornell Medical College, New York, New York 10065, USA
    Discov Med 14:13-20. 2012
    ..The intent of this pilot study is to explore whether [¹⁸F]fluorocholine PET (FCH-PET) can serve as an early predictive biomarker for early detection of RT/CRT response...
  29. ncbi request reprint Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Starr Bldg Rm 340, Weill Medical College of Cornell University and New York Presbyterian Hospital, 520 E 70th St, New York, NY 10021, USA
    J Clin Oncol 23:5696-704. 2005
    ..To evaluate the safety and efficacy of a sequential chemotherapy plus radioimmunotherapy (RIT) regimen in previously untreated follicular non-Hodgkin's lymphoma...
  30. ncbi request reprint Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma
    Lale Kostakoglu
    Division of Nuclear Medicine, Department of Radiology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 94:879-88. 2002
    ....
  31. doi request reprint Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
    John P Leonard
    Department of Medicine, Division of Hematology Oncology, Weill Cornell Medical College, New York, NY, USA
    Blood 119:4597-607. 2012
    ..This study is registered at www.clinicaltrials.gov under identifier NCT00420056...
  32. pmc Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's
    Lisa Mosconi
    New York University School of Medicine, New York, NY 10016, USA
    Proc Natl Acad Sci U S A 107:5949-54. 2010
    ..Present findings may motivate further research on familial transmission and parent-of-origin effects in LOAD...
  33. pmc Possible axonal regrowth in late recovery from the minimally conscious state
    Henning U Voss
    Citigroup Biomedical Imaging Center and Department of Radiology, Weill Medical College of Cornell University, and NeuroOncology Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Invest 116:2005-11. 2006
    ..We propose that axonal regrowth may underlie these findings and provide a biological mechanism for late recovery. Our results are discussed in the context of recent experimental studies that support this inference...
  34. doi request reprint Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model
    Robert M Sharkey
    Center for Molecular Medicine and Immunology, Garden State Cancer Center, 520 Belleville Ave, Belleville, NJ 07109, USA
    Radiology 246:497-507. 2008
    ..To prospectively determine if a bispecific monoclonal antibody (MoAb) pretargeting method with a radiolabeled hapten peptide can depict small (<0.3 mm in diameter) microdisseminated human colon cancer colonies in the lungs of nude mice...